Niranjan Jeganathan, MD
Critical Care Medicine · Loma Linda, CANPI 1578724977
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,473 of the $2,897 with a category attached, or 85.4%. 11 manufacturers reported payments, led by Boehringer Ingelheim at 45.7% of the total. 2025 is the largest year on record at $1,072, 2.0 times the $531 reported in 2019.
Across 40 payments — averaging $72.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$1K
- United Therapeutics Corporation$366
- Genentech, Inc.$327
- Merck$237
- Bayer$200
- GSK$140
- plus $305 from 5 others
Across 11 payments — averaging $7642.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$69K
- Bristol Myers Squibb$9K
- Boehringer Ingelheim International GmbH$6K
What the payments were for
- Consulting fees$2007%
- Travel & lodging$1124%
- Food & beverage$2,47385%
- Education$1124%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 13 | $1,323 |
| United Therapeutics Corporation | 5 | $366 |
| Genentech, Inc. | 5 | $327 |
| Merck | 7 | $237 |
| Bayer | 1 | $200 |
| GSK | 3 | $140 |
| Pulmonx Corporation | 1 | $130 |
| La Jolla Pharmaceutical Company | 2 | $129 |
| Breathe Technologies, Inc. | 1 | $17 |
| AstraZeneca | 1 | $15 |
| Actelion Pharmaceuticals US, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OFEV$721
- Esbriet$212
- Adempas$200
- TYVASO$174
- CHARTIS CATHETER$130
- ZEPHYR DELIVERY CATHETER$130
- ZEPHYR ENDOBRONCHIAL VALVE$130
- PULMONX CHARTIS TABLET CONSOLE$130
- BENLYSTA$125
- WINREVAIR$125
- GIAPREZA$112
How this compares
$2,897 in reported general payments places this provider in the 80th percentile of 715 critical care medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tyvaso DpiTreprostinil | 77 | $1,740,551 |
| OfevNintedanib Esylate | 143 | $1,686,469 |
| Orenitram ErTreprostinil Diolamine | 55 | $659,947 |
| OpsumitMacitentan | 43 | $536,179 |
| AdempasRiociguat | 26 | $345,657 |
| UptraviSelexipag | 12 | $264,083 |
| Ambrisentan | 49 | $262,360 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 136 | $99,190 |
| Tadalafil | 35 | $63,939 |
| AdcircaTadalafil | 14 | $54,893 |
| Spiriva RespimatTiotropium Bromide | 74 | $51,585 |
| Breo ElliptaFluticasone/Vilanterol | 61 | $27,975 |
| Pirfenidone | 23 | $17,933 |
| Spiriva HandihalerTiotropium Bromide | 21 | $16,849 |
| SymbicortBudesonide/Formoterol Fumarate | 42 | $12,662 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $1,323 | $1,747,170228 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $13 | $800,26255 claims |
| BayerAdempas | $200 | $345,65726 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $140 | $127,165197 claims |
| United Therapeutics CorporationAdcirca | $366 | $54,89314 claims |
| AstraZenecaSymbicort | $15 | $12,66242 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 715 critical care medicine providers in California.
Other critical care medicine in Loma Linda
- Hung NguyenLoma Linda$31K
- Cedric Franklin RutlandRiverside$3.2M
- Chinh PhanSacramento$467K
- Timothy AlbertsonSacramento$418K
- Stephen ChenMonterey Park$394K
- Bassam YaghmourOrange$376K
- Xuanha WhiteSan Diego$343K
- Ken YonedaSacramento$173K
- Praveen AkuthotaSan Diego$169K
- Ivan ChengSan Francisco$162K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.